Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H. Machiels, Ezra E.W. Cohen, Thomas Gauler et al.|The Lancet Oncology|2015Cited by 394
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerEzra E.W. Cohen, J.-P. Machiels, Lisa Licitra et al.|Annals of Oncology|2017Cited by 80
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialPaul M. Clément, Jan B. Vermorken, Thomas Gauler et al.|Annals of Oncology|2016Cited by 45
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckBarbara Burtness, Robert I. Haddad, José Dinis et al.|JAMA Oncology|2019Cited by 43